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Abstract
Background: Studies investigating the effect of real-time continuous glucose monitoring (CGM) combined with
pump therapy on glycemic outcomes in type 1 diabetes are increasing. Pump therapy is well established as a
‘‘gold standard’’ for insulin delivery, offering improvements over multiple daily insulin injections. However,
there is still a proportion of subjects using continuous subcutaneous insulin infusion in whom goals for meta-
bolic control are far from achieved or benefits of this type of insulin therapy are transient. The SWITCH (Sensing
With Insulin pump Therapy to Control HbA1c [hemoglobin A1c]) study is a multicenter, randomized, controlled,
crossover study to evaluate if adding CGM to experienced pump patients with suboptimal metabolic control will
provide additional insight enabling clinical and therapeutic benefit.
Methods: Subjects meeting the inclusion criteria were randomized to Sensor On or Sensor Off arms for 6 months,
after a 1-month run-in period. Following a 4-month washout period, the subjects crossed over to the other study
arm for 6 months. The primary end point was the between arm difference in HbA1c levels. Among others,
additional end points include time spent in different glycemic ranges, percentage of patients with HbA1c <7%,
number of hypoglycemic events, glucose variability parameters, safety outcomes, treatment satisfaction, and
quality of life.
Results: Recruitment occurred between January 2008 and February 2009. A total of 153 patients were ran-
domized. Study completion is anticipated in July 2010.
Conclusions: The results will establish if adding CGM to existing, capable, insulin pump users can enable better
metabolic control.
Introduction
Real-time (RT) continuous glucose monitoring (CGM)allows people with diabetes to see their glucose levels
continuously using a subcutaneous sensor, a transmitter, and
a receiving device.1 Accessibility of glucose values enables
recognition of previously undetected glucose levels, direction
and rate of change, and glucose trends. This possibility may
offer benefits over using self-monitoring blood glucose
(SMBG) alone guiding the patients in making lifestyle and
treatment modifications to more effectively manage their di-
abetes. Indeed, the study by Deiss et al.2 and the Juvenile
Diabetes Research Foundation study3 showed that RT-CGM
can be associated with improved glycemic control regardless
of the insulin delivery method in subjects with type 1 diabetes
(T1D). Recently, Raccah et al.4 also demonstrated that in pa-
tients previously naive to continuous subcutaneous insulin
infusion (CSII), when switched to insulin pump, those with a
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sensor-augmented pump system had a better opportunity for
hemoglobin A1c (HbA1c) improvement. Likewise, in spite of a
small sample size, O’Connell et al.5 showed that well-
controlled T1D patients can integrate RT-CGM into existing
CSII treatment in order to improve glycemic control. Con-
sidering reported data, RT-CGM may possibly be viewed as a
behavior-modification tool, and its success is directly depen-
dent on the manner in which it is used.6 In all the previously
mentioned studies there was a positive association between
overall sensor use and glycemic profile benefit.
Crossover studies of longer duration are not a conven-
tionally applied methodology in diabetes. Benefits of this
design include smaller sample size and greater efficiency than
in parallel studies, as between-patient variation is removed as
a subject acts as his or her own control. Challenges to this
methodology include longer study duration and the risks to
protocol compliance, dropouts, missing data, or the undesir-
able effects of carryover. Ludvigsson and Hanas,7 DeVries
et al.,8 and the 5-Nations Trial9 provided examples of cross-
over designs, but these studies compared pump therapy to
multiple daily injection therapy. Only in the study by Lud-
vigsson and Hanas7 was retrospective CGM incorporated in
order to facilitate treatment and patient motivation. The
authors emphasized that the study was conducted at the in-
troduction of CGM into clinical practice, where device inex-
perience created challenges for patient education.7 Similarly,
STAR-1, a sensor-augmented pump versus conventional
pump study, also attributed failure to show significant met-
abolic differences to the newness of the device, use of new
device features by both treatment groups, and frequency of
study visits.10
The aim of the SWITCH (Sensing With Insulin pump
Therapy to Control HbA1c) study is to determine whether
patients with T1D with suboptimal glycemic control already
using CSII can improve metabolic profile using sensor-
augmented pump therapy (SAPT). In this present article the
SWITCH study design and methods are described, in partic-
ular, the crossover design and a selection process, which in-
cludes a run-in period incorporating educational assessment,
to augment subject compliance to the protocol. Hence, the
methodological design described here intends to control for
confounders and elucidate the value of RT-CGM.
Study Design and Methods
The study was conducted in four adult and four pediatric
sites in Europe experienced in personal CGM and insulin
pump therapy. The total study duration for the patient was 17
months, including a run-in period, two 6-month treatment
periods, and a 4-month washout period (Fig. 1). Randomi-
zation was done electronically via case report form according
to a predefined randomization sequence on a 1:1 ratio within
age groups in each center. All HbA1c measurements were sent
to a centralized laboratory for analysis (Laboratorium fu¨r
Klinische Forschung GmbH, Kiel, Germany). A total of 153
subjects were randomized to the study (Fig. 2). The study
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FIG. 1. The SWITCH (Sensing With Insulin pump Therapy to Control HbA1c [hemoglobin A1c]) study design and visit
plan. Color images available online at www.liebertonline.com/dia.
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protocol received institutional Ethics Committee approval at
each of the study centers. A written consent was obtained
from all participants, with additional parent consent for par-
ticipants <18 years old.
Screening
Subjects between 6 years and 70 years of age with T1D for
>1 year and CSII >6 months with suboptimal control (7.5%
HbA1c 9.5%) who were naive to RT-CGM were invited to
take a five-question multiple choice test concerning pump
therapy and general diabetes understanding. If the exam was
passed with 100% outcome, they were invited to join the
study (Visit A). Other inclusion and exclusion criteria are
listed in Table 1.
Run-in phase
Following inclusion, patients were switched to the Bayer
Ascensia Contour glucose meter (without radiofrequency
communication capability) [Bayer Suisse (AG) Diabetes Care,
Zurich, Switzerland] and the Medtronic MiniMed Paradigm
REAL-Time System (Medtronic Inc., Northridge, CA) and re-
ceived retraining on the principles of diabetes therapy and
practical aspects of the pump system (Visit B). The system was
worn for 2 weeks, after which blinded CGM data were col-
lected over the next 2 weeks using the Guardian REAL-Time
System Clinical (Medtronic Inc.) (Visit C). Centers provided
training on sensor insertion and device use. Evaluation of the
subject’s understanding of this training and incorporation of
training given at Visit B were assessed by getting nine correct
answers in a 10-question test. Failure to pass this test resulted in
a screening failure. (See Supplementary Appendix [Supple-
mentary Data are available online at www.liebertonline.dia].)
Treatment periods
Subjects were randomized at Visit 1 to either Sensor ON or
Sensor OFF arms for 6 months. The Sensor ON arm received
additional training and passed the Paradigm REAL-Time
Comprehension exam (90% result on a 12-question test).
Failure to pass this test resulted in re-education in the chal-
lenging areas. Subjects were advised to wear the sensor 85%
of the time in the first 3 weeks to go through the ‘‘learning
curve’’ and any potential challenges with the technology at
this early stage. Subsequently, the subjects were advised to
wear the sensor ‘‘continuously’’ or at minimum 80% for the
duration of the treatment period. The Sensor OFF arm re-
ceived this training and testing at Visit 6, after crossover
following the washout period. Investigators were given a
technical training checklist, and patients were provided op-
tional diaries. For all subjects, study visits occurred every
6 weeks, when devices were uploaded by the medical team
using the Medtronic CareLink Therapy Management Sys-
tem and results were reviewed for treatment optimization.
Visit frequency was determined by the memory capacity of
the device, for example, if all features of the pump were used
at maximum for the Sensor ON arm it would ensure no loss
of data from memory overload. The RT-CGM and pump
profiles for the Sensor ON arm were reviewed to make
therapy adjustments, whereas SMBG data and pump pro-
files were used in the Sensor OFF arm. Patients were re-
quested to perform more than four SMBG tests per day.
Additionally, blinded CGM was collected from the Guardian
REAL-Time Clinical device for 2 weeks prior to each visit in
Sensor OFF arm. No treatment protocols or fixed algorithms
were provided to the centers, and therapy adjustments were
made in partnership with subjects at clinic visits. It remained
the medical responsibility of the treating physician to guide
the subject in reaction to RT-CGM values and hyper- and
hypoglycemic alerts. Subjects were encouraged to make self-
adjustments to their treatment, and examples of therapy
changes were provided in the optional patient diary. Treat-
ment satisfaction questionnaires11 (Diabetes Treatment
Satisfaction Questionnaires, subjects >18 years) and quality
of life questionnaires12 (PedsQL subjects 18 years old) are
given to the subject at the start and end of each treatment
period (Visit B, Visit 5, Visit 6, and Visit 10).
Washout
During this 4-month period, subjects continued with the
provided study devices and wore the blinded device to collect
CGM data 2 weeks before the end of the washout period. No
RT-CGM was used by the subjects during this period. No
other protocol was given to the subject in order to affect
similar conditions between Visit 1 and Visit 6. As we found no
published data on carryover in RT-CGM, the SWITCH study
controlled for a possible carryover effect with a 4-month
washout period, which we defined from unpublished data
from previous studies and the half-life of the HbA1c mea-
surement. Device uploads following the washout period
(Visit 6) were reviewed for evidence of RT-CGM use, and if
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FIG. 2. The SWITCH (Sensing With Insulin pump Therapy
to Control HbA1c [hemoglobin A1c]) CONSORT flow chart
to randomization.
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necessary the washout period could be extended to ensure
compliance.
Sample size estimation and statistical analysis
Sample size of 124 subjects (62 randomized to sequence
ON/OFF and 62 randomized to sequence OFF/ON) was
calculated assuming a two-tailed matched-pairs t test and a
type I error of 5%. With this sample size the study is powered
at 90% to detect a mean difference of 0.3% in HbA1c. An SD of
1.0% has been assumed. In order to account for the duration of
the study and possible dropouts or nonevaluable subjects, the
sample size is increase by approximately 20%, giving a sam-
ple size of 160.
The primary end point is the difference in HbA1c level be-
tween the Sensor ON and the Sensor OFF after 6 months of
follow-up. Mean, SD, and 95% confidence intervals for the
6-month HbA1c level will be reported.
The two groups will be compared using an analysis of
variance adjusting for period effect and declaring subject as
random effect. Period will be included in the model regardless
of statistical significance. A 95% confidence interval and a
P value will be given for the difference of the study arms
based on the analysis of variance model. It is known that
preliminary testing for carryover has harmful effects and
should be avoided;13,14 therefore this has been already ad-
dressed in the design phase of the study by using a 4-month
washout period. Data will be analyzed using Per Protocol as
well as Intent to Treat principles. The Intent to Treat popu-
lation consists of all randomized patients irrespective of their
compliance to the planned course of treatment or deviations
from the protocol. In case of missing data in the Intent to Treat
analysis, measurements from the same study period will be
carried forward to substitute for missing end-of-period val-
ues, if they originate from at least 3 months from start of the
period (Visit 3 in the first period and Visit 8 in the second
period). If no measurements can be carried forward, as a
conservative approach the end-of-period data that are avail-
able only for one period will be used to impute missing data in
the other period. The Per Protocol population for the primary
analysis of HbA1c level is defined as the set of successfully
randomized subjects (regardless of number of SMBG) with
minimum sensor use (Sensor ON arm), with no violation of
entry criteria and who are compliant with the protocol. HbA1c
data will be included in the analysis also in case the associated
blinded sensor data for patients in the Sensor OFF arm are
missing.
Secondary end points will be compared using an analysis of
variance model similar to the one defined for the analysis of
the primary end point. Sensor data for the secondary end
points will be extracted from CareLink Clinical during the 15-
day period prior the end-of-period visit day (Visit 5 and Visit
Table 1. The SWITCH Study Inclusion and Exclusion Criteria
Inclusion criteria
Diagnosed with type 1 diabetes mellitus at least 12 months prior to signature of PIC
Documented suppressed C-peptide (<0.2 nmol) in the patient file measured within the last 3 months, or as evidenced by
central lab value taken at screening
Aged between 6 and 70 years old (inclusive) at signature of PIC (children, 6 years inclusive to 18 years inclusive; adults, 19
years inclusive to 71 years exclusive)
HbA1c (DCCT standard) must be 7.5% and 9.5% as evidenced by central lab value taken at screening
Treated by CSII at least 6 months prior to signature of PIC
Performance of an average of four SMBG tests per day, as evidenced from patient files or SMBG memory recall or meter
downloads
Treated by the investigator’s center for at least 6 months prior to signature of PIC
Female patients of child-bearing potential are using adequate contraception means, as assessed by the investigator.
Exclusion criteria
Patient has previous experience with PRT System or Guardian REAL-Time within 4 months prior to signature of PIC.
Existing pregnancy or intention to conceive (as assessed by investigator)
Hypoglycemic unawareness as assessed by the investigator or evidence of three or more incidents in the last 12 months of
severe hypoglycemia with documented blood glucose below 50 mg/dL, resulting in unconsciousness, hospitalization, or
third-party assistance, where recovery follows treatment with glucose or glucagon or similar
Hearing or vision impairment so that glucose display and alarms cannot be recognized
Documented cutaneous allergy or disease (allergy to sensor or components of the sensor, psoriasis, Staphylococcus,
exanthema, etc.)
Any documented concomitant chronic disease known to affect diabetes control (e.g., altered renal function, active cancer
undergoing treatment, Crohn’s disease, ulcerative colitis, Addison disease) or any concomitant pharmacological
treatment that might modify glycemic values (e.g., chronic corticosteroid therapy), eating disorders, and morbid obesity
(defined as adults with BMI >35 kg/m2 and children with BMI >2 SD for age) as assessed by the investigator
Any other medical, social, or psychological condition that, in the investigator’s opinion, makes the patient unable to
comply with the study protocol and all study procedures
Plans to travel for extended periods (3þ weeks) where the devices cannot be supplied or replaced and/or medical support
is limited (e.g., exotic countries, remote places)
Participation in another clinical study, ongoing or completed less than 3 months prior to signature of PIC
Alcohol or drug abuse, other than nicotine
For pediatric subjects: does not have a reliable support person
BMI, body mass index; CSII, continuous subcutaneous insulin infusion; DCCT, Diabetes Control and Complications Trial; HBA1c,
hemoglobin A1c; PRT, Paradigm REAL-Time; PIC, patient informed consent; SMBG, self-monitoring blood glucose; SWITCH, Sensing With
Insulin pump Therapy to Control HbA1c.
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10 in Fig. 1). Included subjects will have at least 7 days of data.
Summary statistics such as mean, SD, median, range, and
percentiles will be given for additional end points. The sta-
tistical analysis plan for the SWITCH study was externally
reviewed by the Jaeb Center for Health Research, Tampa, FL.
Discussion
The SWITCH study will be the first randomized crossover
trial evaluating the inherent impact of sensor therapy in
children and adults with T1D with suboptimal glycemic
control despite using CSII. The study subjects are established
patients using CSII, yet despite good knowledge of the con-
dition and pump therapy and that they attend a highly ex-
perienced CSII-specialized center, good metabolic control has
still not manifested. The SWITCH study population com-
prised adults and children with almost equal representation
and dictates the same level of sensor usage compliance.
SWITCH intends to elucidate whether the possible glycemic
benefits seen in participants with suboptimal metabolic con-
trol despite previous intensive management with pump
therapy are related to the introduction of RT-CGM, rather
than reflecting the improvement associated to a better use of
CSII technology. Knowledge gained from other studies has
been applied by including assessments of the patient’s level of
knowledge regarding the disease and the therapy via man-
datory tests and, by implementing a training checklist, to
ensure appropriate therapy coverage by the participating
centers teaching RT-CGM.
The last subject visit in SWITCH study is expected in July
2010 and will be followed by comprehensive data analyses.
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